Alltrombosepin- capsules

DIRECTIONS FOR MEDICAL USE

ALLTROMBOSEPINE®

Trade name of the drug: Alltrombosepine®

Active substance (INN): Allium*

Dosage form: capsule

Contents:

1 capsule contains:

Active ingredient: alltrombosepine – 100 mg;

Excipients: aerosil, corn or potato starch, calcium stearate or magnesium stearate.

Description: Solid gelatin capsules, size 2, orange in color, filled with light brown to dark brown powder with a peculiar odor.

Pharmacotherapeutic group: Antiplatelet agent.

ATX code: B01AX

Pharmacological properties

Reduces the binding of ADP to receptors on the surface of platelets, and by inhibiting the activation of GPIIb/IIIa complexes (the main receptor for fibrinogen), inhibits the aggregation of ADP with platelets. Alltrombosepine also prevents platelet aggregation caused by other factors. Alltrombosepine affects ADP by irreversibly altering platelet receptors; normal aggregation activity is restored according to the rate of new platelet formation. From the first days of use, inhibition of platelet aggregation is observed.

Indications for use

  • Treatment of chronic coronary insufficiency;
  • Prevention of thrombosis and embolism, including the risk of myocardial infarction and stroke;
  • Prevention of diseases accompanied by an increased risk of platelet aggregation;

As adjunctive therapy in combination with anticoagulants (heparin) in unstable conditions-unstable advanced angina, myocardial infarction, post-operative period after cardiac surgery and vascular surgery.

Dosage and administration

The drug is prescribed to adults in 100 mg dose after meals with water, once a day.

Side effects

Sensitive patients may have allergic reactions.

Contraindications

  • acute bleeding (peptic ulcer, etc.);
  • High sensitivity to the drug, its components;
  • hemophilia.

Drug interactions

There is a risk of bleeding when using the drug concomitantly with other antiaggregants, thrombolytics or anticoagulants, or agents contributing to thrombocytopenia.

Special indications

The drug is recommended with caution in patients who have a high risk of bleeding due to ulcers, surgical interventions and pathological phenomena. The drug should be kept out of reach of children and should not be used after the expiration date.

Overdose

Symptoms: doses of the drug in excess of the recommended doses may lead to an increased risk of bleeding.

Treatment: Overdose complicated by bleeding requires withdrawal of the drug. Surgical hemostasis, replacement of blood loss, transfusion of fresh frozen plasma, plasmapheresis are possible.

Form of production

Capsules of 100 mg in carton packs or in vials.

Storage conditions

Store in a dry, dark place at temperatures under 25°C. Keep out of the reach of children!

Shelf life

2 years. Do not use after the expiration date.

Conditions of dispensing from pharmacies

Released by a doctor’s prescription.

    ×